# Precipio, Inc.: overview PRPO · Nasdaq · CIK 1043961 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/prpo.md) · [Financials](/companies/prpo/financials.md) · [Filings](/companies/prpo/filings.md) · [Insiders](/companies/prpo/insiders.md) Latest reported revenue: [$7.0m](/filings/0001104659-26-097047.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-097047). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [5,280](/filings/0001104659-25-112601.md) | [5,311 d](/filings/0001104659-26-036878.md) | [4,911](/filings/0001104659-26-061188.md) | [5,629](/filings/0001104659-26-097047.md) | [6,885](/filings/0001104659-25-112601.md) | [6,821 d](/filings/0001104659-26-036878.md) | [6,961](/filings/0001104659-26-061188.md) | [7,021](/filings/0001104659-26-097047.md) | | Gross margin | % | [43.1%](/filings/0001104659-25-112601.md) | [49.8% d](/filings/0001104659-26-036878.md) | [43.6%](/filings/0001104659-26-061188.md) | [43.2%](/filings/0001104659-26-097047.md) | [43.6%](/filings/0001104659-25-112601.md) | [45.9% d](/filings/0001104659-26-036878.md) | [39.1%](/filings/0001104659-26-061188.md) | [44.7%](/filings/0001104659-26-097047.md) | | Operating margin | % | [(11.3%)](/filings/0001104659-25-112601.md) | [(6.3%) d](/filings/0001104659-26-036878.md) | [(17.5%)](/filings/0001104659-26-061188.md) | [(14.6%)](/filings/0001104659-26-097047.md) | [(0.9%)](/filings/0001104659-25-112601.md) | [7.9% d](/filings/0001104659-26-036878.md) | [(20.5%)](/filings/0001104659-26-061188.md) | [(8.5%)](/filings/0001104659-26-097047.md) | | Net margin | % | [(11.9%)](/filings/0001104659-25-112601.md) | [(6.9%) d](/filings/0001104659-26-036878.md) | [(18.0%)](/filings/0001104659-26-061188.md) | [1.3%](/filings/0001104659-26-097047.md) | [(1.1%)](/filings/0001104659-25-112601.md) | [7.7% d](/filings/0001104659-26-036878.md) | [(20.7%)](/filings/0001104659-26-061188.md) | [(3.1%)](/filings/0001104659-26-097047.md) | | Diluted EPS | $ per share | [(0.42)](/filings/0001104659-25-112601.md) | not reported | [(0.59)](/filings/0001104659-26-061188.md) | [0.05](/filings/0001104659-26-097047.md) | [(0.05)](/filings/0001104659-25-112601.md) | not reported | [(0.81)](/filings/0001104659-26-061188.md) | [(0.12)](/filings/0001104659-26-097047.md) | | Free cash flow | $k | [(68.0) d](/filings/0001104659-25-112601.md) | [521 d](/filings/0001104659-26-036878.md) | [(182)](/filings/0001104659-26-061188.md) | [294 d](/filings/0001104659-26-097047.md) | [(44.0) d](/filings/0001104659-25-112601.md) | [291 d](/filings/0001104659-26-036878.md) | [14.0](/filings/0001104659-26-061188.md) | [528 d](/filings/0001104659-26-097047.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [8.7](/filings/0001558370-23-005076.md) | [9.8](/filings/0001558370-24-004365.md) | [15.4](/filings/0001558370-25-003817.md) | [18.6](/filings/0001104659-26-036878.md) | [24.2](/filings/0001104659-26-036878.md) | | Gross margin | % | [27.5%](/filings/0001558370-23-005076.md) | [25.6%](/filings/0001558370-24-004365.md) | [39.0%](/filings/0001558370-25-003817.md) | [40.7%](/filings/0001104659-26-036878.md) | [44.2%](/filings/0001104659-26-036878.md) | | Operating margin | % | [(110.5%)](/filings/0001558370-23-005076.md) | [(130.3%)](/filings/0001558370-24-004365.md) | [(49.4%)](/filings/0001558370-25-003817.md) | [(22.7%)](/filings/0001104659-26-036878.md) | [(5.0%)](/filings/0001104659-26-036878.md) | | Net margin | % | [(97.9%)](/filings/0001558370-23-005076.md) | [(124.0%)](/filings/0001558370-24-004365.md) | [(38.0%)](/filings/0001558370-25-003817.md) | [(23.1%)](/filings/0001104659-26-036878.md) | [(1.5%)](/filings/0001104659-26-036878.md) | | Diluted EPS | $ per share | [(0.40)](/filings/0001558370-23-005076.md) | [(10.73)](/filings/0001558370-24-004365.md) | [(4.51)](/filings/0001558370-25-003817.md) | [(2.93)](/filings/0001104659-26-036878.md) | [(0.23)](/filings/0001104659-26-036878.md) | | Free cash flow | $m | [(7.3)](/filings/0001558370-23-005076.md) | [(8.0)](/filings/0001558370-24-004365.md) | [(3.7)](/filings/0001558370-25-003817.md) | [0.2](/filings/0001104659-26-036878.md) | [0.4](/filings/0001104659-26-036878.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/prpo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.1m | 46,148 | | Added +20,665 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $858.1k | 34,655 | | Added +5,633 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $462.9k | 18,691 | | Reduced −120 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $401.1k | 16,199 | | Reduced −3,101 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $364.3k | 14,714 | | Reduced −402 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $234.0k | 9,450 | | New +9,450 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $232.9k | 9,407 | | Added +62 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $207.9k | 8,396 | | New +8,396 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $8.5k | 343 | | Added +116 | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $1.2k | 50 | | Unchanged | ## Recent filings [All 967 filings](/companies/prpo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-14 | 17:30 ET | [8-K](/filings/0001104659-26-097364.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-097364 | | 2026-08-14 | 16:01 ET | [10-Q](/filings/0001104659-26-097047.md) | Quarterly report, period 2026-06-30 | 0001104659-26-097047 | | 2026-07-31 | 16:45 ET | [8-K](/filings/0001104659-26-089264.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-089264 | | 2026-06-15 | 16:01 ET | [8-K](/filings/0001104659-26-074013.md) | 5.07 Shareholder vote results | 0001104659-26-074013 | | 2026-05-14 | 16:16 ET | [10-Q](/filings/0001104659-26-061188.md) | Quarterly report, period 2026-03-31 | 0001104659-26-061188 | | 2026-05-06 | 17:15 ET | [8-K](/filings/0001104659-26-056360.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-056360 | | 2026-04-28 | 16:30 ET | [DEF 14A](/filings/0001140361-26-017462.md) | Proxy statement, period 2026-06-15 | 0001140361-26-017462 | | 2026-03-30 | 17:34 ET | [10-K](/filings/0001104659-26-036878.md) | Annual report, period 2025-12-31 | 0001104659-26-036878 | | 2026-02-27 | 16:31 ET | [8-K](/filings/0001104659-26-021625.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-021625 | | 2025-12-29 | 17:00 ET | [8-K](/filings/0001104659-25-124902.md) | 5.02 Departure or appointment of officers or directors | 0001104659-25-124902 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-036878.md), filed Mar 30, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/79480bbe-033c-46dd-8008-39259ef6ac4a) ## About the filer - CIK: 1043961 - Tickers: PRPO - Exchange: Nasdaq - SIC code: 3826 Laboratory Analytical Instruments - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:01 ET. No prices; not investment advice.